Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site

Article Abstract:

The ability of monoclonal antibodies to bind to the HIV glycoprotein gp120 and neutralize the virus appears to vary with the strain of HIV and the combination of antibodies used. Two of the monoclonal antibodies evaluated were specific for the V3 loop (V3ab) and the third was specific for the CD4 binding site on gp120 (BSab). Tested alone, all three antibodies significantly neutralized the SF2 and MN strains. The V3ab 447-D and the BSab F105 slightly neutralized the RF strain and the V3ab 257-D had no neutralizing effect on RF. Combining the BSab F105 with either the V3ab 447-D or V3ab 257-D resulted in additive neutralization of the SF2 and MN strains. Combining V3ab 447 with BSab F105 had a supra-additive effect on the neutralization of the RF strain. The degree of cooperativity was not related to antibody concentrations at 25% and 50% activity, suggesting that V3ab binding changes the presentation of gp120, exposing new binding sites and enhancing neutralization.

Physiological aspects, Viruses

---

Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120

Article Abstract:

Human monoclonal antibody (HMab) F105 bound to glycoprotein (gp) 120 on the surfaces of cells infected with five strains of HIV-1 virus and neutralized three of the strains. A laboratory study tested F105's reaction with five isolated strains of HIV-1 virus - SF2, RF, CC, IIIB and MN. F105 reacted with all five strains. F105 neutralized not only the IIIB and MN strains, as has been demonstrated in previous studies, but also the SF2 strain. Neutralization was not affected by the presence of normal or HIV-seropositive serum. Furthermore, additive co-operativity was seen in HIV-seropositive serum in the strains F105 neutralizes. While F105's behavior in the body remains unknown, these findings call for further studies on antibody interactions in mediating neutralization.

---

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

Article Abstract:

Patients with refractory pemphigus vulgaris who had adequate responses to conventional therapy and intravenous immune globulin are observed. It is found that the combination of rituximab and intravenous immune globulin is effective in patients with refractory pemphigus vulgaris.

Biological Product (except Diagnostic) Manufacturing, Biological products exc. diagnostic, Intravenous Immune Globulins, Drug therapy, Dosage and administration, Pemphigus, Intravenous immunoglobulins, Rituximab, Clinical report

Similar abstracts:

• Abstracts: Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen
• Abstracts: Critical care medicine. Risk stratification in unstable angina: prospective validation of the Braunwald classification
• Abstracts: Critical condition: the deaths of two patients who were in desperate need of intensive carehave drawn attention to an acute bed shortage in UK ICUs
• Abstracts: How healthy is school PE? A review of the effectiveness of health-related physical education programmes in schools
• Abstracts: Leg extensions: the real knee-pain culprit? Can muscle change shape: an in-depth examination of bodybuilding's hottest controversy

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.